Every 10-Q that Rezolute, Inc. (RZLT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RZLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RZLT filings page.
Rezolute, Inc. reported a net loss of $16.2M for the quarter and $57.1M for the nine months ended March 31, 2026, as it continues late-stage development of ersodetug for hyperinsulinism. Cash and cash equivalents were $11.2M and marketable debt securities were $109.0M, giving total assets of $125.5M.
Research and development spending reached $38.9M over nine months, focused on the congenital HI sunRIZE study and the tumor HI upLIFT Phase 3 trial. General and administrative expenses were $22.5M, reflecting higher share-based compensation and public company costs.
The company confirmed that sunRIZE did not meet its primary or key secondary endpoints but highlighted pharmacologic activity and glycemic improvements, ongoing open-label extension benefits, and a March 2026 FDA meeting under Breakthrough Therapy designation. Management executed a 29-employee workforce reduction with $1.5M in severance to conserve cash while advancing the upLIFT registrational study, with topline tumor HI data expected in the second half of 2026.
Rezolute, Inc. reported a larger net loss as it advances late-stage programs for hyperinsulinism. For the six months ended December 31, 2025, net loss was $40.9 million, with $27.5 million in research and development and $16.5 million in general and administrative expenses.
In December 2025, its Phase 3 sunRIZE trial in congenital hyperinsulinism failed to meet its primary and key secondary endpoints, prompting a workforce reduction of 29 employees and $1.5 million in one-time severance costs. Management still sees pharmacologic activity for ersodetug and plans an FDA meeting by the end of Q1 2026 to discuss a potential path forward.
The Phase 3 upLIFT trial in tumor hyperinsulinism is ongoing as a single-arm registrational study, with topline data expected in the second half of 2026. As of December 31, 2025, Rezolute held $11.9 million in cash and cash equivalents and $121.0 million in marketable debt securities, and believes this is sufficient to fund operations for at least 12 months.
Rezolute, Inc. (RZLT) filed its quarterly report, highlighting continued late-stage development of ersodetug and typical clinical-stage losses. The company reported a net loss of $18.2 million for the quarter on operating expenses of $19.8 million. Interest and other income was $1.7 million.
Liquidity remains strong with cash and cash equivalents of $9.1 million and investments in marketable debt securities of $143.1 million as of September 30, 2025. Total assets were $158.7 million and shareholders’ equity was $147.2 million. Management believes existing cash and investments will fund operations for at least 12 months.
Key pipeline updates include the Phase 3 sunRIZE study in congenital hyperinsulinism with topline data anticipated in December 2025, and FDA-agreed modifications to the Phase 3 upLIFT trial in tumor hyperinsulinism to a single-arm, open-label design in as few as 16 participants. Capital actions included an April 2025 underwritten offering with approximately $103.5 million gross proceeds and termination of a $50.0 million at-the-market program in October 2025. As of November 4, 2025, 92,727,532 common shares were outstanding.